The present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to collapsible prosthetic transcatheter heart valves that minimize or reduce paravalvular leaks.
Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.
Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two common types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent. To load such valves into a delivery apparatus and deliver them into a patient, the valve is first collapsed or crimped to reduce its circumferential size.
When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size. For balloon-expandable valves, this generally involves releasing the valve, assuring its proper location, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as a sheath covering the valve is withdrawn.
After implantation, imperfect sealing between the prosthetic valve and the native tissue at the site of implantation may cause complications such as paravalvular leakage (“PV leak”) in which retrograde blood flows through one or more gaps formed between the structure of the implanted valve and cardiac tissue as a result of the imperfect sealing.
According to one aspect of the disclosure, a prosthetic heart valve for replacing a native valve includes a stent, a valve assembly, a first cuff, and a filler. The stent extends in a longitudinal direction from an inflow end to an outflow end and has a plurality of stent cells formed by struts, a collapsed condition and an expanded condition. The valve assembly is disposed within the stent. The first cuff is annularly disposed adjacent the stent. The filler is annularly disposed about the stent radially outward of the first cuff and radially outward of the stent. The filler has a first circumferential layer with a first inner wall, a first outer wall, and a plurality of first ribs connecting the first inner wall to the first outer wall. The filler has an expanded condition in which the first inner wall is spaced a first distance from the first outer wall in a radial direction transverse to the longitudinal direction of the stent, and a collapsed condition in which the first inner wall is spaced a second distance from the first outer wall in the radial direction. The first distance is greater than the second distance
Various embodiments of the presently disclosed prosthetic heart valve may be more fully understood with reference to the following detailed description when read with the accompanying drawings, in which:
As used herein in connection with a prosthetic heart valve, the term “inflow end” refers to the end of the heart valve through which blood enters when the valve is functioning as intended, and the term “outflow end” refers to the end of the heart valve through which blood exits when the valve is functioning as intended. As used herein, the term “proximal” refers to the inflow end of a prosthetic heart valve or to elements of a prosthetic heart valve that are relatively close to the inflow end, and the term “distal” refers to the outflow end of a prosthetic heart valve or to elements of a prosthetic heart valve that are relatively close to the outflow end. As used herein, the terms “generally,” “substantially,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified. Like numbers refer to similar or identical elements throughout. When used herein in the context of a prosthetic heart valve, or a component thereof, the lengthwise or axial direction refers to a direction parallel to a longitudinal axis passing through the center of the stent or heart valve from the inflow end to the outflow end. When used herein in the context of a prosthetic heart valve, or a component thereof, the circumferential direction refers to a direction extending along the circumference of the prosthetic heart valve.
Stent 102 may include one or more retaining elements 118 at outflow end 132, the retaining elements being sized and shaped to cooperate with retaining structures provided on a deployment device (not shown). The engagement of retaining elements 118 with the retaining structures on the deployment device may help maintain prosthetic heart valve 100 in assembled relationship with the deployment device, minimize longitudinal movement of the prosthetic heart valve relative to the deployment device during unsheathing or resheathing procedures, and help prevent rotation of the prosthetic heart valve relative to the deployment device as the deployment device is advanced to the target location and during deployment. One such deployment device is described in U.S. Patent Publication No. 2012/0078352, the entire contents of which are hereby incorporated by reference herein.
Stent 102 may also include a plurality of commissure attachment features 116 for mounting the commissures of the valve assembly to the stent. As can be seen in
Prosthetic heart valve 100 includes a valve assembly 104 positioned in the annulus section 140 of stent 102. Valve assembly 104 includes a plurality of leaflets 108 that collectively function as a one way valve by coapting with one another, and a cuff 106 positioned on the luminal surface of stent 102 surrounding leaflets 108. As prosthetic heart valve 100 is intended to replace the aortic valve (which ordinarily is a tri-leaflet valve), it is shown in
Although cuff 106 is shown in
In operation, prosthetic heart valve 100 described above may be used to replace a native heart valve, such as the aortic valve; a surgical heart valve; or a heart valve that has undergone a surgical procedure. Prosthetic heart valve 100 may be delivered to the desired site (e.g., near the native aortic annulus) using any suitable delivery device. During delivery, prosthetic heart valve 100 is disposed inside the delivery device in the collapsed condition. The delivery device may be introduced into the patient using any known percutaneous procedure, such as a transfemoral, transapical, or transseptal delivery procedure. Once the delivery device has reached the target site, the user may deploy prosthetic heart valve 100. Upon deployment, prosthetic heart valve 100 expands into secure engagement within the native aortic annulus. When prosthetic heart valve 100 is properly positioned inside the heart, it works as a one-way valve, allowing blood to flow in one direction and preventing blood from flowing in the opposite direction.
In order to help minimize or eliminate PV leak, for example through the gaps 200 shown in
Although described as a single piece of material above, outer cuff 350 may comprise multiple pieces of material that, when joined together, form a similar shape and provide similar function as described above for the outer cuff. Also, rather than being formed of a single substantially rectangular piece of material that is wrapped around the circumference of stent 302, outer cuff 350 may be formed as a continuous annular web without side edges 354, 356. Preferably, outer cuff 350 has an axial height measured from its proximal edge 352 to its distal edge 358 that is approximately half the axial height of a cell 312 in the proximalmost row of cells in stent 302 as measured along the major axis of the cell between two of its apices when the cell is in an expanded condition. However, outer cuff 350 may have other suitable heights, such as the full axial height of a cell 312 in the proximalmost row of cells, or more or less than the full axial height of a cell 312 in the proximalmost row of cells. Still further, although inner cuff 306 and outer cuff 350 are described above as separate pieces of material joined to stent 302 and to each other, the cuffs may be formed integrally with one another from a single piece of material that is wrapped around the proximal edge of the stent, with the distal edge 358 of the outer portion of the cuff joined to the stent and/or to the inner portion of the cuff at attachment points S1 as described above. With this configuration, the proximal edge 352 of outer cuff 350 does not need to be sutured to stent 302, although it still may be preferable to provide such attachment. Inner cuff 306 and outer cuff 350 may be formed of the same or different materials, including any suitable biological material or polymer such as, for example, polytetrafluoroethylene (PTFE), ultra-high molecular weight polyethylene (UHMWPE), polyurethane, polyvinyl alcohol, silicone, or combinations thereof.
For outer cuff 350 of prosthetic heart valve 300 to effectively mitigate PV leak, blood flowing in the retrograde direction around the outside of stent 302 preferably is readily able to enter the space between the outer cuff and inner cuff 306. Although the pressure prevailing during ventricular diastole may facilitate the movement of outer cuff 350 radially away from inner cuff 306 to provide an opening therebetween through which retrograde blood may flow, causing the outer cuff to billow outwardly to thus provide additional sealing, additional structures may be provided to assist the outer cuff to move radially away from the inner cuff to facilitate mitigation of PV leak. For example,
Filler 400 preferably has a ring or annulus shape, and may include one or more layers in a radially stacked configuration. In the illustrated embodiment, filler 400 includes three layers 410a-c, although it should be understood that in other embodiments, the filler may include a single layer, two layers, or more than three layers. Each layer 410a-c may include a plurality of individual cells 420a-c extending circumferentially around the respective layer. Layer 410a may include an inner wall 430a and an outer wall 440a positioned radially outward of the inner wall. Layers 410b-c may similarly include inner walls 430b-c and outer walls 440b-c. Radially adjacent layers may include walls that are common to one another, or that are formed separately and then joined together. For example, outer wall 440a of layer 410a may be the same structure as inner wall 430b of layer 410b, or alternately they may be separate structures that are joined together. Each layer 410a-c may include a plurality of ribs 450a-c extending from the respective inner walls 430a-c to the respective outer walls 440a-c. Each cell 420a-c is bounded by a respective inner wall 430a-c, a respective outer wall 440a-c, and two respective ribs 450a-c that are adjacent one another. In the illustrated embodiment, the top or outflow end of each cell 420a-c is open, and the bottom or inflow end of each cell is open, although in other embodiments described in greater detail below, the inflow and/or outflow ends of each cell may be closed.
Preferably, in the absence of applied force, filler 400 is in an expanded condition such as that shown in
In one example, filler 400 may be formed of an elastomeric material, such as a polyurethane-silicone copolymer. Other suitable materials for filler 400 include, but are not limited to, poly (styrene-b-isobutylene-b-styrene) and silicone. The elasticity of filler 400 may aid the filler to tend to be in the expanded condition in the absence of constraining forces. In other words, if filler 400 is constrained into the collapsed condition, the elasticity of the material forming the filler may cause the filler to transition to the expanded condition upon removal of the constraint. Depending on the particular material chosen for filler 400, and the strength of that material, inner walls 430a-c, outer walls 440a-c, and ribs 450a-c may each have a small thickness. For example, certain polyurethane-silicone polymers may provide enough strength so that the inner walls 430a-c, outer walls 440a-c, and ribs 450a-c may each have a small thickness. Minimizing the thickness of inner walls 430a-c, outer walls 440a-c, and ribs 450a-c is preferable in order to help maintain a small profile when filler 400 and prosthetic heart valve 300 are transitioned to a collapsed condition for delivery into a patient. However, it will be understood that it is also preferable that inner walls 430a-c, outer walls 440a-c, and ribs 450a-c are strong enough to return to the expanded condition after being released from a constraint keeping filler 400 in the collapsed condition. That strength may be determined at least in part by the thickness of inner walls 430a-c, outer walls 440a-c, and ribs 450a-c, as well as by the material properties of the particular material forming filler 400. It should further be understood that the overall thickness of filler 400 may be increased, if desired, by adding additional layers, increasing the length of ribs 450a-c, and/or increasing the thickness of inner walls 430a-c and/or outer walls 440a-c.
In order to help filler 400 maintain a relatively small profile in the collapsed condition, it is preferable that the vertices of the cells 420a-c in one of layers 410a-c be offset in the circumferential direction from the vertices of the cells in any of the other layers. That is, because the thickness of the cell vertices may be greater than the thicknesses of inner walls 430a-c, outer walls 440a-c, and ribs 450a-c, it is desirable that the vertices do not overlie one another in the radial direction of filler 400. For example, each rib 450a has one point of connection to outer wall 440a of layer 410a and another point of connection to inner wall 430a of layer 410a, each of which may be referred to as a vertex of a corresponding cell 420a. Similarly, each rib 450b has a point of connection to outer wall 440b of layer 410b and a point of connection to inner wall 430b of layer 410b, each of which may be referred to as a vertex of a corresponding cell 420b. Preferably, these two sets of vertices are offset from one another in the circumferential direction so that they do not overlie one another in the radial direction of filler 400. In other words, a radius line drawn from the center of filler 400 to the outermost layer 410c of the filler preferably will not extend through a vertex of a cell 420a in layer 410a and a cell 420b in layer 410b. More preferably, such radius line also will not extend through a vertex of a cell 420c in layer 410c. Since filler 400 may have a slightly greater thickness at these vertices, staggering the vertices in the circumferential direction so that they do not overlie one another in the radial direction may help reduce the profile of the filler in the collapsed condition compared to a similar filler that includes radially aligned vertices. Still more preferably, the points of connection of ribs 450a with outer wall 440a are positioned equidistantly between the points of connection of connecting ribs 450b with inner wall 430b. The points of connections of ribs 450b with outer wall 440b are preferably similarly staggered or offset in the circumferential direction relative to the points of connection of ribs 450c with inner wall 430c. If additional layers are included in filler 400, it is preferable that this pattern continues so that the ribs of radially adjacent layers do not have radially overlapping points of connection, or that any such overlap is minimized.
As noted above, filler 400 may be positioned between outer cuff 350 and stent 302 of prosthetic heart valve 300. The height of filler 400 from the proximal (or inflow) end to the distal (or outflow) end may be about equal to the height of outer cuff 350 between proximal edge 352 and distal edge 358 so that the filler may completely fill the space between the outer cuff and the ablumenal surface of stent 302. In other embodiments, the proximal-to-distal height of filler 400 may be smaller than the proximal-to-distal height of outer cuff 350 so that the filler only partially fills the space between the outer cuff and the ablumenal surface of stent 302. Filler 400 may be attached to stent 302, inner cuff 306, and/or outer cuff 350 in any suitable manner, including sutures, adhesives, heat setting/curing, and overmolding. Further, when using filler 400 with prosthetic heart valve 300, it may be preferable that the distal edge 358 of outer cuff 350 is attached only to filler 400, and not to stent 302 or inner cuff 306. With this attachment configuration, the entire length of the distal edge 358 of outer cuff 350 may be spaced a distance apart in the radial direction from inner cuff 306 and stent 302, maximizing the area for retrograde blood to flow into the space between the outer cuff and the inner cuff and/or stent. However, in other embodiments, outer cuff 350 may be attached to stent 302 and/or inner cuff 306 as shown in
In operation, prosthetic heart valve 300, with filler 400 positioned between outer cuff 350 and inner cuff 306, may be transitioned into a collapsed condition and loaded onto a delivery device for delivery into a patient. Prosthetic heart valve 300 may be advanced to the aortic valve of the patient while it is maintained in the collapsed condition, for example by an overlying sheath of the delivery device that radially constrains the prosthetic heart valve. Once at the desired location, such as the native aortic valve, the overlying sheath may be removed from prosthetic heart valve 300, removing the constraining force. In the absence of any constraining forces, prosthetic heart valve 300, along with filler 400, returns to the expanded condition. As filler 400 expands, it may push outer cuff 350 radially outwardly into any gaps between prosthetic heart valve 300 and the native aortic annulus. During normal operation, if any blood flows in the retrograde direction around the outside of stent 302, that blood may flow into the space between outer cuff 350 and inner cuff 306, with filler 400 helping to maintain an opening between the distal edge 358 of the outer cuff and the inner cuff. Blood flowing into the space between inner cuff 306 and outer cuff 350 may result in the outer cuff billowing outwardly to some degree to further seal any remaining spaces between prosthetic heart valve 300 and the native aortic valve annulus, helping to mitigate or eliminate PV leak.
In the illustrated embodiment, when filler 400 is positioned between outer cuff 350 and inner cuff 306 of prosthetic heart valve 300, the proximal and distal ends of the filler may remain open so that a channel extends through each cell 420a-c from the proximal end to the distal end. If blood does flow into the space between inner cuff 306 and outer cuff 350 during operation, that blood may flow through the channels in cells 420a-c, which may help to further expand filler 400 radially outwardly. At least because the proximal edge 352 of outer cuff 350 is coupled to inner cuff 306, blood entering the space between the outer cuff and inner cuff is trapped within that volume.
End cap 500 may be generally annular or ring shaped and have expanded and collapsed conditions. In the illustrated embodiment, end cap 500 includes a first innermost ring-shaped channel 510a, a second ring-shaped channel 510b positioned radially outwardly of the first channel, and a third ring-shaped channel 510c positioned radially outwardly of the first and second channels. Each channel 510a-c may be formed from an inner wall 530a-c and an outer wall 540a-c. Channels 510a-c may each have a longitudinal cross-sectional shape of a “V,” a half-diamond, or another shape that allows the inner wall 530a-c of a channel to collapse toward the corresponding outer wall 540a-c of the channel. Each inner wall 530a-c may be coupled to the corresponding outer wall 540a-c of the same channel 510a-c so that blood is unable to pass across the areas where the inner walls are attached to the outer walls, for example at the vertex of the “V”-shape.
One or two end caps 500 may be coupled to filler 400. In the illustrated example, end cap 500 includes the same number of channels 510a-c as the number of layers 410a-c of filler 400. With this configuration, an end cap 500 may be coupled to either the proximal or distal end of filler 400 so that inner walls 530a-c align with corresponding inner walls 430a-c, and outer walls 540a-c align with corresponding outer walls 440a-c. If a single end cap 500 is coupled to the proximal end of filler 400, retrograde blood flow into the distal end of filler 400 will pass through cells 420a-c of layers 410a-c and into corresponding channels 510a-c, with end cap 500 limiting or preventing that blood from passing back through the native valve annulus.
If filler 400 is coupled to a prosthetic heart valve that is identical to prosthetic heart valve 300 but without an outer cuff 350, it is preferable to couple a first end cap 500 to the proximal end of filler 400. With this configuration, the prosthetic heart valve may be loaded into a delivery device and deployed at the native heart valve annulus in the same manner as described above, with filler 400 expanding into any gaps between the prosthetic heart valve and the native valve annulus. It should be understood that filler 400 is preferably sufficiently pliable to conform to the shape of the native valve annulus. During retrograde flow of blood around the outside of the prosthetic heart valve, blood may flow into cells 420a-c through the distal end of filler 400. The blood flow may cause filler 400 to further expand, with end cap 500 ensuring that the blood does not exit the proximal end of the filler. Rather than leave the distal end of filler 400 open, a second end cap 500 may be coupled to the distal end of the filler so that both the proximal and distal ends of the filler are sealed. In such arrangement, retrograde blood flow around the outside of the prosthetic heart valve will not enter the cells 420a-c of the filler. If the expansion of filler 400 is sufficient to seal any gaps existing between the prosthetic heart valve and the native valve annulus, the ability of blood to enter cells 420a-c may not confer a significant additional benefit. On the other hand, there may be a risk that contact of blood with the relatively large surface area of inner walls 430a-c, outer walls 440a-c, and ribs 450a-c may result in thrombus formation. By sealing the proximal and distal ends of filler 400 with end caps 500, blood will not enter cells 420a-c, reducing or eliminating the risk of thrombus formation by contact of blood with the interior space of the filler. As noted above, end caps 500 may be positioned on both the proximal and distal ends of filler 400 even when used in combination with an outer cuff 350. That particular embodiment may similarly reduce the likelihood of thrombus formation by reducing or eliminating the contact between blood and the interior structures of filler 400, with the filler still helping to push outer cuff 350 radially outwardly to help seal against PV leak. If desired, a single end cap 500 may be used with filler 400 in conjunction with a prosthetic valve having an outer cuff 350, either on the proximal or distal end of the filler.
In some embodiments, end cap 500 may be coupled to the proximal and/or distal ends of filler 400 by any suitable method including, for example, sutures, adhesives, heat setting/curing, and overmolding. In other embodiments, end cap 500 may be formed integrally with filler 400, such that the end cap does not need to be separately attached to the filler. End cap 500 may be made from any suitable material, including those mentioned above in connection with filler 400. In some embodiments, filler 400 and end cap 500 both may be made from the same material as one another. In embodiments in which end cap 500 has the same number of channels 510a-c as filler 400 has layers 410a-c, it may be preferable that the end cap is coupled to the filler so that each channel of the end cap remains aligned with a corresponding layer of the filler as the assembly is expanded or contracted. However, it should be understood that end cap 500 need not have a number of channels 510a-c equal to the number of layers 410a-c of filler 400. For example, end cap 500 may have more or fewer channels than the number of layers of filler 400. Rather, end cap 500 preferably includes structures that allow for its connection to filler 400 in a manner that seals the filler against blood entering (or exiting) the filler where the end cap is attached, and that further allow for the end cap to collapse and expand along with the filler.
It should be understood that although filler 400 and optional end cap(s) 500 are described in connection with a prosthetic aortic valve, the same or similar items may be used in conjunction with a prosthetic heart valve for implantation into the mitral valve, the tricuspid valve, or the pulmonary valve.
In addition, although the term “filler” is used herein to describe certain structures that may help to fill certain space between a prosthetic heart valve and adjacent native tissue when implanted, or otherwise to fill space between an inner and an outer cuff of a prosthetic heart valve, the term “filler” itself is not limited to any particular structure or particular function. In other words, according to one aspect of the disclosure, a “filler” is described as having a first circumferential layer with a first inner wall, a first outer wall, and a plurality of first ribs connecting the first inner wall to the first outer wall. It should be understood that, in that particular example of a filler, any structure having a first circumferential layer with a first inner wall, a first outer wall, and a plurality of first ribs connecting the first inner wall to the first outer wall, may be considered a “filler.” In addition, the term “filler” does not imply or require (i) that the “filler” structure be filled with anything, or (ii) that the “filler” structure functions to filler any other structure.
While filler 400 (with or without end cap 500) has been described herein in conjunction with prosthetic heart valve 300 that includes outer cuff 350, it should be understood that the filler (with or without the end cap) could be used in conjunction with a prosthetic heart valve without an outer cuff, such as prosthetic heart valve 100. Still further, filler 400 (with our without end cap 500) could be used in conjunction with various other collapsible prosthetic heart valves, including, for example, those described in U.S. Pat. Nos. 8,808,356 and/or 8,425,593 and/or U.S. Patent Publication No. 2018/0055631 and/or U.S. Patent Publication No. 2018/0116798, the disclosures of which are each hereby incorporated by reference herein.
According to a first aspect of the disclosure, a prosthetic heart valve for replacing a native valve comprises:
a stent extending in a longitudinal direction from an inflow end to an outflow end and having a plurality of stent cells formed by struts, a collapsed condition and an expanded condition;
a valve assembly disposed within the stent;
a filler annularly disposed about the stent radially outward of the first cuff and radially outward of the stent, the filler having a first circumferential layer with a first inner wall, a first outer wall, and a plurality of first ribs connecting the first inner wall to the first outer wall,
wherein the filler has an expanded condition in which the first inner wall is spaced a first distance from the first outer wall in a radial direction transverse to the longitudinal direction of the stent, and a collapsed condition in which the first inner wall is spaced a second distance from the first outer wall in the radial direction, the first distance being greater than the second distance; and/or
the filler extends from a proximal end to a distal end, the proximal end of the filler being positioned nearer the inflow end of the stent than is the distal end of the filler; and/or
the first circumferential layer of the filler includes a plurality of first cells extending from the proximal end of the filler to the distal end of the filler; and/or
each of the plurality of first cells is defined by the first inner wall, the first outer wall, and two adjacent ones of the plurality of first ribs; and/or
in the expanded condition of the filler, each of the plurality of first cells has a shape of a parallelogram in transverse cross-section; and/or
the filler has a second circumferential layer with a second inner wall, a second outer wall, and a plurality of second ribs connecting the second inner wall to the second outer wall, the second circumferential layer being positioned radially outward of the first circumferential layer; and/or
the second inner wall of the second circumferential layer and the first outer wall of the first circumferential layer are integral with one another; and/or
each first rib connects to the first outer wall of the first circumferential layer at a first connecting point, and each second rib connects to the second inner wall of the second circumferential layer at a second connecting point, each first connecting point being offset in a circumferential direction between a pair of adjacent second connecting points; and/or
a second cuff having a proximal edge facing toward the inflow end of the stent and a distal edge facing toward the outflow end of the stent, the second cuff being annularly disposed about the stent radially outward of the filler; and/or
the distal edge of the second cuff is coupled directly to the stent at a plurality of locations spaced apart from one another in a circumferential direction of the stent; and/or
the distal edge of the second cuff is coupled directly to the filler at a plurality of locations spaced apart from one another in a circumferential direction of the filler; and/or
the distal edge of the second cuff is not directly coupled to the stent; and/or
a collapsible and expandable end cap positioned at the proximal end of the filler so that fluid entering the distal end of the filler between the first inner wall and second inner wall of the first circumferential layer is restricted from exiting the filler through the proximal end; and/or
the end cap is integral with the filler; and/or
the end cap has a first inner wall coupled to the first inner wall of the first circumferential layer of the filler, and a first outer wall coupled to the first outer wall of the first circumferential layer of the filler; and/or
a second cuff having a proximal edge facing toward the inflow end of the stent and a distal edge facing toward the outflow end of the stent, the second cuff being annularly disposed about the stent radially outward of the filler, the first circumferential layer of the filler being in fluid communication with an outside of the filler via the distal end of the filler; and/or
a collapsible and expandable first end cap positioned at the proximal end of the filler, and a collapsible and expandable second end cap positioned at the distal end of the filler, so that an interior of the first circumferential layer of the filler is not in fluid communication with an exterior of the filler; and/or
the filler includes a radial outermost layer that is uncovered so that, upon implantation of the prosthetic heart valve in a native valve annulus, the radial outermost layer of the filler is configured to directly contact the native valve annulus; and/or
a second cuff having a proximal edge facing toward the inflow end of the stent and a distal edge facing toward the outflow end of the stent, the second cuff being annularly disposed about the stent radially outward of the filler; and/or
the first end cap and the second end cap are integral with the filler.
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims. For example, features of one embodiment described above may be combined with features of other embodiments described above.
This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 62/576,204, filed Oct. 24, 2017, the disclosure of which is hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
4275469 | Gabbay | Jun 1981 | A |
4491986 | Gabbay | Jan 1985 | A |
4759758 | Gabbay | Jul 1988 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4922905 | Strecker | May 1990 | A |
4994077 | Dobben | Feb 1991 | A |
5163955 | Love | Nov 1992 | A |
5258023 | Reger | Nov 1993 | A |
5411552 | Andersen et al. | May 1995 | A |
5415664 | Pinchuk | May 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5755783 | Stobie | May 1998 | A |
5843167 | Dwyer et al. | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5935163 | Gabbay | Aug 1999 | A |
5961549 | Nguyen et al. | Oct 1999 | A |
6045576 | Starr | Apr 2000 | A |
6077297 | Robinson et al. | Jun 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6090140 | Gabbay | Jul 2000 | A |
6214036 | Letendre et al. | Apr 2001 | B1 |
6264691 | Gabbay | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6368348 | Gabbay | Apr 2002 | B1 |
6371983 | Lane | Apr 2002 | B1 |
6419695 | Gabbay | Jul 2002 | B1 |
6425916 | Garrison | Jul 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6468660 | Ogle et al. | Oct 2002 | B2 |
6488702 | Besselink | Dec 2002 | B1 |
6517576 | Gabbay | Feb 2003 | B2 |
6533810 | Hankh et al. | Mar 2003 | B2 |
6582464 | Gabbay | Jun 2003 | B2 |
6610088 | Gabbay | Aug 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6685625 | Gabbay | Feb 2004 | B2 |
6716244 | Klaco | Apr 2004 | B2 |
6719789 | Cox | Apr 2004 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6783556 | Gabbay | Aug 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6869444 | Gabbay | Mar 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6951573 | Dilling | Oct 2005 | B1 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7137184 | Schreck | Nov 2006 | B2 |
7160322 | Gabbay | Jan 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7247167 | Gabbay | Jul 2007 | B2 |
7267686 | DiMatteo et al. | Sep 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7311730 | Gabbay | Dec 2007 | B2 |
7320704 | Lashinski et al. | Jan 2008 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7374573 | Gabbay | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7452371 | Pavcnik et al. | Nov 2008 | B2 |
7510572 | Gabbay | Mar 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7524331 | Birdsall | Apr 2009 | B2 |
7534261 | Friedman | May 2009 | B2 |
RE40816 | Taylor et al. | Jun 2009 | E |
7585321 | Cribier | Sep 2009 | B2 |
7628805 | Spenser et al. | Dec 2009 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7731742 | Schlick et al. | Jun 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7824442 | Salahieh et al. | Nov 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7846204 | Letac et al. | Dec 2010 | B2 |
7857845 | Stacchino et al. | Dec 2010 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7959666 | Salahieh et al. | Jun 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
7988724 | Salahieh et al. | Aug 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
D648854 | Braido | Nov 2011 | S |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052741 | Bruszewski et al. | Nov 2011 | B2 |
8052749 | Salahieh et al. | Nov 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8075611 | Millwee et al. | Dec 2011 | B2 |
D652926 | Braido | Jan 2012 | S |
D652927 | Braido et al. | Jan 2012 | S |
D653341 | Braido et al. | Jan 2012 | S |
D653342 | Braido et al. | Jan 2012 | S |
D653343 | Ness et al. | Jan 2012 | S |
D654169 | Braido | Feb 2012 | S |
D654170 | Braido et al. | Feb 2012 | S |
8137398 | Tuval et al. | Mar 2012 | B2 |
8142497 | Friedman | Mar 2012 | B2 |
D660432 | Braido | May 2012 | S |
D660433 | Braido et al. | May 2012 | S |
D660967 | Braido et al. | May 2012 | S |
8167936 | Kurian | May 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8221493 | Boyle et al. | Jul 2012 | B2 |
8230717 | Matonick | Jul 2012 | B2 |
8231670 | Salahieh et al. | Jul 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8257434 | Matheny | Sep 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8313525 | Tuval et al. | Nov 2012 | B2 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8323336 | Hill et al. | Dec 2012 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8348995 | Tuval et al. | Jan 2013 | B2 |
8348996 | Tuval et al. | Jan 2013 | B2 |
8348998 | Pintor et al. | Jan 2013 | B2 |
8366769 | Huynh | Feb 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8408214 | Spenser | Apr 2013 | B2 |
8414643 | Tuval et al. | Apr 2013 | B2 |
8425593 | Braido et al. | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8449604 | Moaddeb et al. | May 2013 | B2 |
D684692 | Braido | Jun 2013 | S |
8454686 | Alkhatib | Jun 2013 | B2 |
8500798 | Rowe et al. | Aug 2013 | B2 |
8568474 | Yeung et al. | Oct 2013 | B2 |
8579962 | Salahieh et al. | Nov 2013 | B2 |
8579966 | Seguin et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8591575 | Cribier | Nov 2013 | B2 |
8597349 | Alkhatib | Dec 2013 | B2 |
8603159 | Seguin et al. | Dec 2013 | B2 |
8603160 | Salahieh et al. | Dec 2013 | B2 |
8613765 | Bonhoeffer et al. | Dec 2013 | B2 |
8623074 | Ryan | Jan 2014 | B2 |
8652204 | Quill et al. | Feb 2014 | B2 |
8663322 | Keranen | Mar 2014 | B2 |
8668733 | Haug et al. | Mar 2014 | B2 |
8685080 | White | Apr 2014 | B2 |
8728154 | Alkhatib | May 2014 | B2 |
8747459 | Nguyen et al. | Jun 2014 | B2 |
8764820 | Dehdashtian et al. | Jul 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8801776 | House et al. | Aug 2014 | B2 |
8808356 | Braido et al. | Aug 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8834563 | Righini | Sep 2014 | B2 |
8840661 | Manasse | Sep 2014 | B2 |
8840663 | Salahieh et al. | Sep 2014 | B2 |
8876894 | Tuval et al. | Nov 2014 | B2 |
8876895 | Tuval et al. | Nov 2014 | B2 |
8940040 | Shahriari | Jan 2015 | B2 |
8945209 | Bonyuet et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8974523 | Thill et al. | Mar 2015 | B2 |
8974524 | Yeung et al. | Mar 2015 | B2 |
9220594 | Braido | Dec 2015 | B2 |
9326856 | Schraut | May 2016 | B2 |
9398951 | Alkhatib | Jul 2016 | B2 |
9532868 | Braido | Jan 2017 | B2 |
9668858 | Morin | Jun 2017 | B2 |
9757230 | Fahim | Sep 2017 | B2 |
9820852 | Braido | Nov 2017 | B2 |
10143551 | Braido | Dec 2018 | B2 |
10271949 | Dakin | Apr 2019 | B2 |
10321991 | Glimsdale | Jun 2019 | B2 |
20020036220 | Gabbay | Mar 2002 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030130726 | Thorpe et al. | Jul 2003 | A1 |
20040049262 | Obermiller et al. | Mar 2004 | A1 |
20040093075 | Kuehne | May 2004 | A1 |
20040111111 | Lin | Jun 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050203605 | Dolan | Sep 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050256566 | Gabbay | Nov 2005 | A1 |
20060008497 | Gabbay | Jan 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060122692 | Gilad et al. | Jun 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
20060173532 | Flagle et al. | Aug 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060195180 | Kheradvar et al. | Aug 2006 | A1 |
20060206202 | Bonhoeffer et al. | Sep 2006 | A1 |
20060241744 | Beith | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060259120 | Vongphakdy et al. | Nov 2006 | A1 |
20060259137 | Artof | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060276813 | Greenberg | Dec 2006 | A1 |
20060276874 | Wilson et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070027534 | Bergheim et al. | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070055358 | Krolik et al. | Mar 2007 | A1 |
20070067029 | Gabbay | Mar 2007 | A1 |
20070093890 | Eliasen et al. | Apr 2007 | A1 |
20070100435 | Case et al. | May 2007 | A1 |
20070118210 | Pinchuk | May 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070244545 | Birdsall et al. | Oct 2007 | A1 |
20070244552 | Salahieh et al. | Oct 2007 | A1 |
20070288087 | Fearnot et al. | Dec 2007 | A1 |
20080021552 | Gabbay | Jan 2008 | A1 |
20080039934 | Styrc | Feb 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080114452 | Gabbay | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147183 | Styrc | Jun 2008 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080255662 | Stacchino et al. | Oct 2008 | A1 |
20080262602 | Wilk et al. | Oct 2008 | A1 |
20080269879 | Sathe et al. | Oct 2008 | A1 |
20090099653 | Suri et al. | Apr 2009 | A1 |
20090112309 | Jaramillo et al. | Apr 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090276027 | Glynn | Nov 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100036484 | Hariton et al. | Feb 2010 | A1 |
20100049306 | House et al. | Feb 2010 | A1 |
20100087907 | Lattouf | Apr 2010 | A1 |
20100131055 | Case et al. | May 2010 | A1 |
20100168778 | Braido | Jul 2010 | A1 |
20100168839 | Braido et al. | Jul 2010 | A1 |
20100168844 | Toomes et al. | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100204781 | Alkhatib | Aug 2010 | A1 |
20100204785 | Alkhatib | Aug 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100234940 | Dolan | Sep 2010 | A1 |
20100249911 | Alkhatib | Sep 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100286768 | Alkhatib | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110054466 | Rothstein et al. | Mar 2011 | A1 |
20110098800 | Braido et al. | Apr 2011 | A1 |
20110098802 | Braido et al. | Apr 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110172765 | Nguyen et al. | Jul 2011 | A1 |
20110208283 | Rust | Aug 2011 | A1 |
20110264206 | Tabor | Oct 2011 | A1 |
20120035722 | Tuval | Feb 2012 | A1 |
20120059458 | Buchbinder | Mar 2012 | A1 |
20120071969 | Li | Mar 2012 | A1 |
20120078347 | Braido et al. | Mar 2012 | A1 |
20120078352 | Wang et al. | Mar 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120303116 | Gorman, III et al. | Nov 2012 | A1 |
20130274873 | Delaloye et al. | Oct 2013 | A1 |
20140005778 | Buchbinder | Jan 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140155997 | Braido | Jun 2014 | A1 |
20140214159 | Vidlund et al. | Jul 2014 | A1 |
20140228946 | Chau et al. | Aug 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350668 | Delaloye et al. | Nov 2014 | A1 |
20140350669 | Gillespie et al. | Nov 2014 | A1 |
20180055631 | Morin et al. | Mar 2018 | A1 |
20180116798 | Perszyk | May 2018 | A1 |
Number | Date | Country |
---|---|---|
19857887 | Jul 2000 | DE |
10121210 | Nov 2002 | DE |
102005003632 | Aug 2006 | DE |
202008009610 | Dec 2008 | DE |
0850607 | Jul 1998 | EP |
1000590 | May 2000 | EP |
1584306 | Oct 2005 | EP |
1598031 | Nov 2005 | EP |
1360942 | Dec 2005 | EP |
1926455 | Jun 2008 | EP |
2537487 | Dec 2012 | EP |
2850008 | Jul 2004 | FR |
2847800 | Oct 2005 | FR |
9117720 | Nov 1991 | WO |
9716133 | May 1997 | WO |
9832412 | Jul 1998 | WO |
9913801 | Mar 1999 | WO |
01028459 | Apr 2001 | WO |
0149213 | Jul 2001 | WO |
01054625 | Aug 2001 | WO |
01056500 | Aug 2001 | WO |
01076510 | Oct 2001 | WO |
0236048 | May 2002 | WO |
0247575 | Jun 2002 | WO |
02067782 | Sep 2002 | WO |
03047468 | Jun 2003 | WO |
2005070343 | Aug 2005 | WO |
06073626 | Jul 2006 | WO |
2007053243 | May 2007 | WO |
07071436 | Jun 2007 | WO |
08070797 | Jun 2008 | WO |
10008548 | Jan 2010 | WO |
10008549 | Jan 2010 | WO |
10096176 | Aug 2010 | WO |
10098857 | Sep 2010 | WO |
Entry |
---|
Ruiz, Carlos, Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies, Euro PCR—dated May 25, 2010. |
Percutaneous aortic valve replacement: resection before implantation, 836-840, Quaden, Rene et al., European J. of Cardio-thoracic Surgery, 27 (2005). |
Catheter-implanted prosthetic heart valves, Knudsen, L.L., et al., The International Journal of Artificial Organs, vol. 16, No. 5 1993, pp. 253-262. |
Transluminal Aortic Valve Placement, Moazami, Nader, et al., ASAIO Journal, 1996; 42:M381-M385. |
Transluminal Catheter Implanted Prosthetic Heart Valves, Andersen, Henning Rud, International Journal of Angiology 7:102-106 (1998). |
Transluminal implantation of artificial heart valves, Andersen, H. R., et al., European Heart Journal (1992) 13, 704-708. |
Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?, 579-584, Zegdi, Rachid, MD, PhD et al., J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008. |
“Direct-Access Valve Replacement”, Christoph H. Huber, et al., Journal of the American College of Cardiology, vol. 46, No. 2, (Jul. 19, 2005). |
“Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, John G. Webb et al., Circulation, 2006; 113:842-850 (Feb. 6, 2006). |
“Minimally invasive cardiac surgery”, M. J. Mack, Surgical Endoscopy, 2006, 20:S488-S492, DOI: 10.1007/s00464-006-0110-8 (presented Apr. 24, 2006). |
“Transapical Transcatheter Aortic Valve Implantation in Humans”, Samuel V. Lichtenstein et al., Circulation. 2006; 114: 591-596 (Jul. 31, 2006). |
“Closed heart surgery: Back to the future”, Samuel V. Lichtenstein, The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, pp. 941-943. |
“Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”; Th. Walther et al., European Journal of Cardio-thoracic Surgery 29 (2006) 703-708 (Jan. 30, 2006). |
“Transapical aortic valve implantation: an animal feasibility study”; Todd M. Dewey et al., The annals of thoracic surgery 2006; 82: 110-6 (Feb. 13, 2006). |
Textbook “Transcatheter Valve Repair”, 2006, pp. 165-186. |
Rohde, I., Masch, J.-M., Theisen-Kunde, D., Marczynski-Bühlow, M., Bombien Quaden, R., Lutter, G. and Brinkmann, R. (2015), Resection of Calcified Aortic Heart Leaflets In Vitro by Q-Switched 2?μm Microsecond Laser Radiation. Journal of Cardiac Surgery, 30: 157-162. doi: 10.1111/jocs.12481. |
Muñoz, Daniel Rodríguez, Carla Lázaro Rivera, and José Luis Zamorano Gómez. “Guidance of treatment of perivalvular prosthetic leaks.” Current cardiology reports 16.1 (2014): 1-6. |
Gössl, Mario, and Charanjit S. Rihal. “Percutaneous treatment of aortic and mitral valve paravalvular regurgitation.” Current cardiology reports 15.8 (2013): 1-8. |
Swiatkiewicz, Iwona, et al. “Percutaneous closure of mitral perivalvular leak.” Kardiologia polska 67.7 (2009): 762. |
De Cicco, Giuseppe, et al. “Aortic valve periprosthetic leakage: anatomic observations and surgical results.” The Annals of thoracic surgery 79.5 (2005): 1480-1485. |
Heat Advisor, “Heart repairs without surgery. Minimally invasive procedures aim to correct valve leakage”, Sep. 2004, PubMed ID 15586429. |
Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks, Hourihan et al., Journal of the American College of Cardiology, vol. 20, No. 6, pp. 1371-1377, (1992). |
Buellesfeld et al., Treatment of paravalvular leaks through inverventional techniques; Department of Cardiology, Ben University Hospital 2011. |
Number | Date | Country | |
---|---|---|---|
20190117387 A1 | Apr 2019 | US |
Number | Date | Country | |
---|---|---|---|
62576204 | Oct 2017 | US |